| Related LncRNAs | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| ID | lncRNA Name | Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source |
| EL0014 | AATBC | bladder cancer | microarray, qPCR, in vitro knockdown etc. | bladder cancer tissue | up-regulated | interaction | We found that AATBC was overexpressed in bladder cancer patient tissues and positively correlated with tumor grade and pT stage. We also found that inhibition of AATBC resulted in cell proliferation arrest through G1 cell cycle mediated by cyclin D1, CDK4, p18 and phosphorylated Rb. In addition, inhibition of AATBC induced cell apoptosis through the intrinsic apoptosis signaling pathway, as evidenced by the activation of caspase-9 and caspase-3. The investigation for the signaling pathway revealed that the apoptosis following AATBC knockdown was mediated by activation of phosphorylated JNK and suppression of NRF2. | 25473900 | Lnc2Cancer |
| EL0244 | BLACAT1 | bladder cancer | microarray, qPCR, knockdown, ISH etc. | bladder cancer tissue, cell lines (J82, UMUC-3, HT-1376, T24, 5637 etc.) | up-regulated | N/A | qPCR confirmed that linc-UBC1 expression is up-regulated in 60 cases (58.8%) in bladder cancer tissues compared with normal adjacent tissues, and its overexpression correlates with lymph node metastasis and poor survival. Further functional analysis demonstrated that knockdown of linc-UBC1 attenuates bladder cancer cell proliferation, motility, invasion, colony formation ability, tumorigenicity and metastatic potential. RIP and ChIP assay confirmed that linc-UBC1 physically associates with PRC2 complex and regulates histone modification status of target genes. | 23688781 | Lnc2Cancer |
| EL0244 | BLACAT1 | bladder cancer | N/A | N/A | N/A | expression | Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs | 24006935 | LncRNADisease |
| EL0260 | C5orf66-AS1 | bladder cancer | microarray, qPCR, knockdown etc. | bladder cancer tissue | down-regulated | N/A | Four lncRNAs were selected for further confirmation of microarray results using qPCR. These lncRNAs were among the most downregulated or upregulated lncRNAs. Data analysis showed that KRT19P3 was upregulated and TNXA, CTA-134P22.2 and CTC-276P9.1 were downregulated in bladder cancer samples compared with matched normal tissues.these deregulated lncRNAs play a key or partial role in the development and/or progression of bladder cancer. | 24944692 | Lnc2Cancer |
| EL0266 | CADM3-AS1 | bladder cancer | microarray, qPCR, knockdown etc. | bladder cancer tissue | down-regulated | N/A | Four lncRNAs were selected for further confirmation of microarray results using qPCR. These lncRNAs were among the most downregulated or upregulated lncRNAs. Data analysis showed that KRT19P3 was upregulated and TNXA, CTA-134P22.2 and CTC-276P9.1 were downregulated in bladder cancer samples compared with matched normal tissues.these deregulated lncRNAs play a key or partial role in the development and/or progression of bladder cancer. | 24944692 | Lnc2Cancer |
| EL0289 | CDKN2B-AS1 | bladder cancer | qPCR, Western blot etc. | bladder cancer specimens and the corresponding adjacent non-tumor tissues | up-regulated | interaction | Our results showed up-regulation of ANRIL in bladder cancer tissues versus the corresponding adjacent non-tumor tissues. Knockdown of ANRIL repressed cell proliferation and increased cell apoptosis, along with decreased expression of Bcl-2 and increased expressions of Bax, cytoplasmic cytochrome c and Smac and cleaved caspase-9, caspase-3 and PARP. | 26449463 | Lnc2Cancer |
| EL0526 | GAS5 | bladder cancer | qPCR, Western blot, knockdown, RIP etc. | bladder cancer tissue, cell lines (T24, DSH1, RT112, RT4, KU7, 253J etc.) | down-regulated | N/A | In the present study, we found that the GAS5 expression is commonly downregulated in bladder cancer cell lines and human specimens. Knockdown of GAS5 promotes bladder cancer cell proliferation, whereas forced expression of GAS5 suppresses cell proliferation. We further demonstrated that knockdown of GAS5 increases CDK6 mRNA and protein levels in bladder cancer cells. Expectedly, GAS5 inhibition induces a significant decrease in G0/G1 phase and an obvious increase in S phase. | 24069260 | Lnc2Cancer |
| EL0533 | GHET1 | bladder cancer | qPCR, Western blot, in vitro knockdown etc. | bladder cancer tissue | up-regulated | expression | In this study, we demonstrated that GHET1 was upregulated in bladder cancer tissues compared to adjacent normal tissues and its over-expression correlates with tumor size, advanced tumor and lymph node status, and poor survival. GHET1 knockdown suppressed the proliferation and invasion of bladder cancer cells in vitro. In the meantime, inhibition of GHET1 reversed the epithelial-mesenchymal-transition in bladder cancer cell line. | 25400817 | Lnc2Cancer |
| EL0556 | H19 | bladder cancer | ISH etc. | bladder cancer tissue etc. | differential expression | expression | The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. | 11193051 | LncRNADisease Lnc2Cancer |
| EL0556 | H19 | bladder cancer | microarray, qPCR, knockdown, ISH etc. | cell lines (T24P etc.) | up-regulated | N/A | The H19 non-coding RNA is essential for human tumor growth. | 17786216 | LncRNADisease Lnc2Cancer |
| EL0556 | H19 | bladder cancer | N/A | N/A | N/A | regulation | Control of imprinting. Containing miRNA miR-675. | 22996375 | LncRNADisease |
| EL0556 | H19 | bladder cancer | N/A | N/A | N/A | expression | Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs | 24006935 | LncRNADisease |
| EL0556 | H19 | bladder cancer | N/A | N/A | N/A | expression | Prognostic marker low-risk marker Oncogene targeted therapy agent | 24373479 | LncRNADisease |
| EL0556 | H19 | bladder cancer | N/A | N/A | N/A | regulation | Control of imprinting breast, cervix, oesophagus prostate, endometrial, colon | 24499465 | LncRNADisease |
| EL0556 | H19 | bladder cancer | PCR-RFLP etc. | blood | differential expression | mutation | A significantly decreased risk of bladder cancer was found for the rs2839698 TC genotype but not for CC homozygotes.The rs2839698 TC genotype was especially associated with a reduced risk of developing non-muscle-invasive disease. Borderline significantly | 18262338 | LncRNADisease Lnc2Cancer |
| EL0556 | H19 | bladder cancer | qPCR, ISH etc. | cell lines (T24P, HT-1376 etc.) | up-regulated | N/A | Bladder tumors may be successfully treated by intravesical instillation of the double promoter vector H19-DTA-P4-DTA. | 21162716 | LncRNADisease Lnc2Cancer |
| EL0556 | H19 | bladder cancer | qPCR, Luciferase reporter assay, in vitro knockdown, RIP etc. | bladder cancer tissue, cell lines (RT4, RT112, DSH1, 253J, TCCSUP etc.) | up-regulated | regulation | Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. | 23354591 | LncRNADisease Lnc2Cancer |
| EL0556 | H19 | bladder cancer | qPCR, Western blot etc. | bladder cancer tissue, cell lines (RT4, RT112, DSH1, 253J, TCCSUP etc.) | up-regulated | regulation | Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. | 23399020 | LncRNADisease Lnc2Cancer |
| EL0556 | H19 | bladder cancer | qPCR, Western blot etc. | bladder cancer tissue, cell lines (5637, UMUC-3, EJ) | up-regulated | interaction | YAP1 and H19 expression levels were markedly elevated in bladder cancer tissues and cells, and H19 expression was found to be significantly associated with YAP1 expression. YAP1 and H19 were overexpressed were associated with poorer clinicopathologic prognosis. In addition, YAP1 was found to enhance H19 expression, whereas H19 had no significant effect on YAP1 expression in bladder cancer cells. | 26163939 | Lnc2Cancer |
| EL0556 | H19 | bladder cancer | qPCR, Western blot, Luciferase reporter assays, knockdown etc. | bladder cancer tissues, cell lines (RT4, HT-1376, 5637, 253J, TCCSUP, T24,and J82) | up-regulated | interaction | We found that miR-675 expression levels were remarkably increased in bladder cancer tissues as compared with adjacent noncancerous tissues or normal bladder tissue from health donors; moreover, enhanced miR-675 expression was also observed in bladder cancer cell lines. Ectopic expression of H19 significantly increased bladder cancer cell proliferation and miR-675 expression in vitro | 26198047 | Lnc2Cancer |
| EL0570 | HIF1A-AS2 | bladder cancer | SV-HUC-1 cells | bladder cancer tissue and cells | up-regulated | N/A | Overexpression of HIF1A-AS2 in SV-HUC-1 cells could promote cell proliferation cell migration and anti-apoptosis | 27018306 | |
| EL0578 | HOTAIR | bladder cancer | qPCR, Western blot etc. | bladder cancer tissue, cell lines (T24, J82, BIU-87 etc.) | up-regulated | expression | Ninety out of 110 specimens were detected in HOTAIR high expression. Histological grade and expression levels of HOTAIR were positively correlated with the recurrence rate. HOTAIR expression (hazard ratio 4.712; 95 % CI 2.894-8.714; P < 0.001) was an independent predictor of recurrence rate in multivariate Cox regression analysis. HOTAIR expression is correlated with patients' poor prognosis. | 25030736 | Lnc2Cancer |
| EL0578 | HOTAIR | bladder cancer | qPCR, Western blot etc. | bladder cancer tissue | up-regulated | interaction | Our findings indicate that HOTAIR expression has prognostic value for bladder cancer progression, recurrence, and survival and suggest that HOTAIR plays active roles in modulating the cancer epigenome, becoming an interesting candidate as a target for cancer diagnosis and therapy. The observed HOTAIR regulation by EZH2 and the possibility of modulating EZH2 activity with specific inhibitors open new possible paths to be explored in bladder cancer therapy | 26457124 | Lnc2Cancer |
| EL0578 | HOTAIR | bladder cancer | qPCR, Western blot, Northern blot etc. | cell lines(HCV29, 5637, T24, J82, SW780 ) | up-regulated | interaction | We have identified cyclin J (CCNJ) gene, which is involved in cell cycle regulation, as a novel target for miR-205. Furthermore, a long non-coding RNA HOTAIR (HOX transcript antisense RNA) was observed to participate in the silencing of miR-205 in bladder cancer cells by breaking the balance of histone modification between H3K4me3 (histone H3 at lysine 4 methylation) and H3K27me3 on miR-205 promoter. | 26469956 | Lnc2Cancer |
| EL0635 | KRT19P3 | bladder cancer | microarray, qPCR, knockdown etc. | bladder cancer tissue | up-regulated | N/A | Four lncRNAs were selected for further confirmation of microarray results using qPCR. These lncRNAs were among the most downregulated or upregulated lncRNAs. Data analysis showed that KRT19P3 was upregulated and TNXA, CTA-134P22.2 and CTC-276P9.1 were downregulated in bladder cancer samples compared with matched normal tissues.these deregulated lncRNAs play a key or partial role in the development and/or progression of bladder cancer. | 24944692 | Lnc2Cancer |
| EL0802 | lncRNA-n336928 | bladder cancer | microarray, qPCR etc. | bladder cancer tissue | up-regulated | expression | Results showed that the expression level of lncRNA-n336928 (noncode database ID: n336928) was significantly higher in bladder cancer tissues compared to that in adjacent noncancerous tissues (P < 0.001). Collectively, our study shows that high expression of lncRNA-n336928 is associated with the progression of bladder cancer, and that lncRNA-n336928 might serve as a biomarker for prognosis of bladder cancer. | 26551459 | Lnc2Cancer |
| EL0853 | MALAT1 | bladder cancer | N/A | N/A | N/A | expression | Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs | 24006935 | LncRNADisease |
| EL0853 | MALAT1 | bladder cancer | N/A | N/A | N/A | regulation | Oncogene | 24373479 | LncRNADisease |
| EL0853 | MALAT1 | bladder cancer | qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. | bladder cancer tissue, cell lines (T24, RT4 etc.) | up-regulated | N/A | TGFβ1 induces malat1 expression and EMT in bladder cancer cells. malat1 overexpression is significantly correlated with poor survival in patients with bladder cancer. malat1 and E-cadherin expression is negatively correlated in vitro and in vivo. malat1 knockdown inhibits TGFβ1 induced EMT. malat1 is associated with suz12, and this association results in decrease of E-cadherin expression and increase of N-cadherin and fibronectin expression. Targeted inhibition of malat1 or suz12 suppresses the migratory and invasive properties induced by TGFβ1 We demonstrated that malat1 or suz12 knockdown inhibits tumor metastasis in animal models. | 24449823 | Lnc2Cancer |
| EL0853 | MALAT1 | bladder cancer | qPCR, Western bolt, Luciferase reporter assay etc. | bladder cancer tissue, cell line (T24) | up-regulated | N/A | We verified that MALAT-1 levels were upregulated in bladder cancer tissues compared with adjacent normal tissues, and MALAT-1 expression was remarkably increased in primary tumors that subsequently metastasized, when compared to those primary tumors that did not metastasize. levels. We further demonstrated that MALAT-1 promoted EMT by activating Wnt signaling in vitro. | 22722759 | Lnc2Cancer |
| EL0859 | MDC1-AS1 | bladder cancer | microarray, qPCR etc. | bladder cancer tissue | down-regulated | interaction | The expression levels of MDC1-AS and MDC1 was down-regulated in bladder cancer. After over-expression of MDC1-AS, increased levels of MDC1 were observed in bladder cancer cells. We also found a remarkably inhibitory role of antisense lncRNA MDC1-AS on malignant cell behaviors in bladder cancer cells EJ and T24. | 25514464 | Lnc2Cancer |
| EL0861 | MEG3 | bladder cancer | N/A | N/A | N/A | expression | Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs | 24006935 | LncRNADisease |
| EL0861 | MEG3 | bladder cancer | N/A | N/A | N/A | regulation | Tumour suppressor | 24373479 | LncRNADisease |
| EL0861 | MEG3 | bladder cancer | qPCR, ISH etc. | breast cancer tissue | down-regulated | expression | MEG3 expression is lost. | 14602737 | LncRNADisease Lnc2Cancer |
| EL0861 | MEG3 | bladder cancer | qPCR, Western blot etc. | bladder cancer tissue, cell line (T24) | down-regulated | regulation | Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. | 23295831 | LncRNADisease Lnc2Cancer |
| EL1052 | PCAT1 | bladder cancer | qPCR etc. | bladder cancer tissue, cell lines (T24, 5637 etc.) | up-regulated | expression | In this study, we found that PCAT-1 was up-regulated in bladder cancer compared to paired normal urothelium.PCAT-1 plays oncogenic roles. | 25934337 | Lnc2Cancer |
| EL1102 | PVT1 | bladder cancer | qPCR, knockdown, Flow cytometry assay etc. | bladder cancer tissue, cell lines (T24, 5637) | up-regulated | expression | Here, we found that PVT1 was upregulated in bladder cancer tissues and cells. Further experiments revealed that PVT1 promoted cell proliferation and suppressed cell apoptosis. | 26517688 | Lnc2Cancer |
| EL1180 | SCHLAP1 | bladder cancer | real-time qPCR | Bladder cancer T24 and 5637 cells | up-regulated | N/A | Cell growth arrest, apoptosis induction and migration inhibition | 26861061 | |
| EL1226 | SNHG16 | bladder cancer | N/A | N/A | N/A | regulation | putative diagnostic, prognostic, and predictive marker | 24373479 | LncRNADisease |
| EL1226 | SNHG16 | bladder cancer | qPCR etc. | bladder cancer tissue, cell lines (RT4, T24, J82 etc.) | up-regulated | N/A | Expression of ncRAN was significantly higher in bladder cancers compared with normal tissues and in invasive tumor compared with superficial ones (P < .01). Consistently, ncRAN expressed significantly higher in invasive bladder tumor cell lines (5637, T24, J82) than that in superficial tumor cell line (RT4). Overexpression of ncRAN in RT4 cells significantly enhanced cell proliferation, migration, and invasion. Silencing of ncRAN improved chemotherapy sensitivity in 5637 cells. | 21147498 | Lnc2Cancer |
| EL1240 | SPRY4-IT1 | bladder cancer | qPCR, knockdown etc. | bladder cancer tissue, cell lines (J82, T24, SW780, SV-40 etc.) | up-regulated | expression | SPRY4-IT1 levels were highly positively correlated with histological grade, tumor stage, and lymph node metastasis and reduced overall survival. A multivariate analysis showed that SPRY4-IT1 expression is an independent prognostic factor of overall survival in patients with UCB. | 25973088 | Lnc2Cancer |
| EL1250 | SUMO1P3 | bladder cancer | N/A | bladder cancer tissues | up-regulated | expression | Up-regulated SUMO1P3 expression was positively correlated with greater histological grade (P<0.05) and advanced TNM stage (P<0.05). cell proliferation / migration inhibition and apoptosis induction were also observed in SUMO1P3 siRNA-transfected bladder cancer cells. SUMO1P3 plays oncogenic roles in bladder cancer and can be used as a potential prognostic and therapeutic target. | 26799188 | |
| EL1347 | TNXA | bladder cancer | microarray, qPCR, knockdown etc. | bladder cancer tissue | down-regulated | N/A | Four lncRNAs were selected for further confirmation of microarray results using qPCR. These lncRNAs were among the most downregulated or upregulated lncRNAs. Data analysis showed that KRT19P3 was upregulated and TNXA, CTA-134P22.2 and CTC-276P9.1 were downregulated in bladder cancer samples compared with matched normal tissues.these deregulated lncRNAs play a key or partial role in the development and/or progression of bladder cancer. | 24944692 | Lnc2Cancer |
| EL1399 | TUG1 | bladder cancer | N/A | N/A | N/A | expression | Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs | 24006935 | LncRNADisease |
| EL1399 | TUG1 | bladder cancer | N/A | N/A | N/A | regulation | Putative diagnostic and prognostic marker; oncogene | 24373479 | LncRNADisease |
| EL1399 | TUG1 | bladder cancer | qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. | bladder cancer tissue, | up-regulated | interaction | We confirmed that TUG1 was overexpressed in bladder cancer tissues and established cell lines. Knockdown of TUG1 inhibited bladder cancer cell metastasis both in vitro and in vivo. Furthermore, we found that TUG1 promoted cancer cell invasion and radioresistance through inducing epithelial-to-mesenchymal transition (EMT). Interestingly, TUG1 decreased the expression of miR-145 and there was a reciprocal repression between TUG1 and miR-145 in an Argonaute2-dependent manner. ZEB2 was identified as a down-stream target of miR-145 and TUG1 exerted its function through the miR-145/ZEB2 axis. | 26318860 | Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | microarray, qPCR, Northern blot etc. | bladder cancer tissue, cell lines (TCC, BLS-211, BLZ-211 etc.) | up-regulated | expression | UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. | 18501714 | LncRNADisease Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | microarray, qPCR, Western blot, Luciferase reporter assay, knockdown etc. | bladder cancer tissue, cell lines (RT4, T24 etc.) | up-regulated | regulation | Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. | 24495014 | LncRNADisease Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | N/A | N/A | N/A | expression | Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs | 24006935 | LncRNADisease |
| EL1431 | UCA1 | bladder cancer | N/A | N/A | N/A | expression | Diagnostic marker oncogene | 24373479 | LncRNADisease |
| EL1431 | UCA1 | bladder cancer | qPCR etc. | bladder cancer tissue | up-regulated | expression | UCA1 was identified as a novel noncoding RNA gene dramatically up-regulated in TCC (bladder transitional cell carcinoma) and it is the most TCC-specific gene yet identified. | 16914571 | LncRNADisease Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | qPCR etc. | cell line (BLZ-211) | up-regulated | N/A | After knocking down of UCA1 in BLZ-211 cells, several cell cycle-related genes (CDKN2B, EP300 and TGFβ-2) were screened by microarray assay and validated by qPCR. Taken together, we concluded that UCA1 regulated cell cycle through CREB via PI3K-AKT dependent pathway in bladder cancer. | 22285928 | Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | qPCR etc. | bladder cancer tissue | up-regulated | expression | With a high level of sensitivity and specificity, UCA1 is a promising urinary marker for the diagnosis of bladder cancer. | 22490897 | LncRNADisease Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | qPCR etc. | cell lines (BLZ-211, 5637, UM-UC-2 etc.) | up-regulated | expression | Overexpression of UCA1a(CUDR) significantly enhanced proliferation, migration and invasion of the bladder cancer cell line UM-UC-2. | 22576688 | LncRNADisease Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | qPCR etc. | urine | up-regulated | interaction | Compared to control groups, the malignant group had higher expression levels of miR-210, miR-96, and lncRNA-UCA1. | 26138586 | Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | qPCR etc. | urine | up-regulated | expression | The detected lncRNA-UCA1 level was significantly lower in healthy donors and benign groups compared to bladder cancer samples. | 26161701 | Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | qPCR, ISH etc. | cell lines (BLS-211, BLX-211, BLZ-211 etc.) | up-regulated | expression | In adult human tissues, UCA1 gene was not expressed except in the heart and spleen. The expression level of UCA1 was increased in 8 common tumor tissues as compared with that in the corresponding normal tissues. | 20117985 | LncRNADisease Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | qPCR, Luciferase reporter assays, knockdown etc. | cell lines (5637, T24, BLZ-211, BLS-211) | up-regulated | expression | Upregulation of long non-coding RNA urothelial carcinoma associated 1 by CCAAT/enhancer binding protein α contributes to bladder cancer cell growth and reduced apoptosis. | 24648007 | LncRNADisease Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | qPCR, Western blot, in vitro knockdown, RIP etc. | bladdder cancer tissue | up-regulated | N/A | In the present study, we first examined the function of UCA1 in 5637 bladder cancer cells, which express high levels of UCA1. We found that UCA1 plays an oncogene-like role in this bladder cancer cell line, which is consistent with previous reports. Furthermore, we found UCA1 promotes 5637 cell proliferation by antagonizing the activities of BRG1, by reducing its binding to the p21 promoter and inhibiting its chromatin remodeling activity.UCA1 impairs both binding of BRG1 to the p21 promoter and chromatin remodeling activity of BRG1. | 24993775 | Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | qPCR, Western blot, knockdown etc. | bladder cancer cell lines | up-regulated | N/A | In this study, we show that lncRNA UCA1 promotes glycolysis in bladder cancer cells, and that UCA1-induced hexokinase 2 (HK2) functions as an important mediator in this process. We further show that UCA1 activates mTOR to regulate HK2 through both activation of STAT3 and repression of microRNA143. | 24890811 | Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | qPCR, Western blot, knockdown etc. | bladder cancer tissue | up-regulated | N/A | Here, we report that downregulated hsa-miR-1 and upregulated lncRNA urothelial cancer associated 1 (UCA1) were inversely expressed in bladder cancer. Hsa-miR-1 decreased the expression of UCA1 in bladder cancer cells in an Ago2-slicer-dependent manner. The binding site between UCA1 and hsa-miR-1 was confirmed. Overexpression of hsa-miR-1 inhibited bladder cancer cell growth, induced apoptosis, and decreased cell motility. hsamiR-1 to play tumor suppressive roles via downregulating lncRNA UCA1 in bladder cancer, which may have potential therapeutic significance. | 25015192 | Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | qPCR, Western blot, Luciferase reporter assay etc. | bladder cancer tissue, cell lines (UMUC2, 5637) | up-regulated | interaction | Real-time reverse transcriptase-polymerase chain reaction demonstrated that the RNA level of urothelial carcinoma-associated 1 and GLS2 was positively correlated in bladder cancer tissues and cell lines. | 26373319 | Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | qPCR, Western blot, Luciferase reporter assay etc. | bladder cancer tissue, cell lines (5637, T24, UMUC2) | up-regulated | interaction | Here, we demonstrated that overexpression of lncRNA-UCA1 could induce epithelial to mesenchymal transition (EMT) and increase the migratory and invasive abilities of bladder cancer cells. Mechanistically, lncRNA-UCA1 induced EMT of bladder cancer cells by upregulating the expression levels of zinc finger E-box binding homeobox 1 and 2 (ZEB1 and ZEB2), and regulated bladder cancer cell migration and invasion by tumor suppressive hsa-miR-145 and its target gene the actin-binding protein fascin homologue 1 (FSCN1). | 26544536 | Lnc2Cancer |
| EL1431 | UCA1 | bladder cancer | qPCR, Western blot, Luciferase reporter assay, knockdown etc. | cell lines (5637, T24) | up-regulated | N/A | LncRNA-UCA1 was upregulated by hypoxia in bladder cancer cells. Under hypoxic conditions, lncRNA-UCA1 upregulation increased cell proliferation, migration, and invasion and inhibited apoptosis. The underlying mechanism of hypoxia-upregulated lncRNA-UCA1 expression was that HIF-1a specifically bound to HREs in the lncRNA-UCA1 promoter. Furthermore, HIF-1a knockdown or inhibition could prevent lncRNA-UCA1 upregulation under hypoxia. | 24737584 | Lnc2Cancer |
| EL1459 | XIST | bladder cancer | N/A | N/A | N/A | regulation | Putative diagnostic and prognostic marker | 24373479 | LncRNADisease |
| EL1516 | ZEB2-AS1 | bladder cancer | qPCR etc. | bladder cancer cell lines (T24, 5637 and J82) | up-regulated | interaction | A long non-coding RNA, ZEB2NAT, was demonstrated to be essential for this TGFβ1-dependent process. ZEB2NAT depletion reversed CAF-CM-induced EMT and invasion of cancer cells, as well as reduced the ZEB2 protein level. Consistently, TGFβ1 mRNA expression is positively correlated with ZEB2NAT transcript and ZEB2 protein levels in human bladder cancer specimens. | 26152796 | Lnc2Cancer |